SGLT inhibitors as antidiabetic agents: a comprehensive review

Diabetes is one of the most common disorders that substantially contributes to an increase in global health burden. As a metabolic disorder, diabetes is associated with various medical conditions and diseases such as obesity, hypertension, cardiovascular diseases, and atherosclerosis. In this review...

Full description

Saved in:
Bibliographic Details
Published in:RSC advances 2020-01, Vol.1 (3), p.1733-1756
Main Authors: Kshirsagar, Rahul P, Kulkarni, Abhishek A, Chouthe, Rashmi S, Pathan, Shahebaaz K, Une, Hemant D, Reddy, G. Bhanuprakash, Diwan, Prakash V, Ansari, Siddique Akber, Sangshetti, Jaiprakash N
Format: Article
Language:English
Subjects:
Atherosclerosis
Chemistry
Diabetes
Hypertension
Inhibitors
Metabolic disorders
Organic chemistry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c428t-6b213bf234c7940e45212be9b579ed109d051a587b9964a09a59247fdcc2eb723
cites cdi_FETCH-LOGICAL-c428t-6b213bf234c7940e45212be9b579ed109d051a587b9964a09a59247fdcc2eb723
container_end_page 1756
container_issue 3
container_start_page 1733
container_title RSC advances
container_volume 1
creator Kshirsagar, Rahul P
Kulkarni, Abhishek A
Chouthe, Rashmi S
Pathan, Shahebaaz K
Une, Hemant D
Reddy, G. Bhanuprakash
Diwan, Prakash V
Ansari, Siddique Akber
Sangshetti, Jaiprakash N
description Diabetes is one of the most common disorders that substantially contributes to an increase in global health burden. As a metabolic disorder, diabetes is associated with various medical conditions and diseases such as obesity, hypertension, cardiovascular diseases, and atherosclerosis. In this review, we cover the scientific studies on sodium/glucose cotransporter (SGLT) inhibitors published during the last decade. Our focus on providing an exhaustive overview of SGLT inhibitors enabled us to present their chemical classification for the first time. Diabetes is one of the most common disorders that substantially contributes to an increase in global health burden.
doi_str_mv 10.1039/c9ra08706k
format article
fullrecord <record><control><sourceid>proquest_rsc_p</sourceid><recordid>TN_cdi_proquest_miscellaneous_2658652200</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2335014752</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-6b213bf234c7940e45212be9b579ed109d051a587b9964a09a59247fdcc2eb723</originalsourceid><addsrcrecordid>eNpdkVtLw0AQhRdRVNQX35WALyJE956sD4VSvGFB8PK87G4mdrVN6m5S8d-b2lovw8AMzMfhDAehfYJPCWbqzKlgcJ5h-bqGtinmMqVYqvVf-xbai_EFdyUFoZJsoi0muOIyY9uo93A1fEx8NfLWN3WIiem6anzhjYXGu8Q8Q9XE88Qkrp5MA4ygin4GSYCZh_ddtFGacYS95dxBT5cXj4PrdHh3dTPoD1PHad6k0lLCbEkZd5niGLighFpQVmQKCoJVgQUxIs-sUpIbrIxQlGdl4RwFm1G2g3oL3WlrJ1C4zlMwYz0NfmLCh66N138vlR_p53qmFeY5zXkncLwUCPVbC7HREx8djMemgrqNmkqRS0Epxh169A99qdtQde9pypjAhGdi7uhkQblQxxigXJkhWM-T0QN13_9K5raDD3_bX6HfOXTAwQII0a2uP9GyT-bbkbI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2335014752</pqid></control><display><type>article</type><title>SGLT inhibitors as antidiabetic agents: a comprehensive review</title><source>PubMed Central (Open Access)</source><creator>Kshirsagar, Rahul P ; Kulkarni, Abhishek A ; Chouthe, Rashmi S ; Pathan, Shahebaaz K ; Une, Hemant D ; Reddy, G. Bhanuprakash ; Diwan, Prakash V ; Ansari, Siddique Akber ; Sangshetti, Jaiprakash N</creator><creatorcontrib>Kshirsagar, Rahul P ; Kulkarni, Abhishek A ; Chouthe, Rashmi S ; Pathan, Shahebaaz K ; Une, Hemant D ; Reddy, G. Bhanuprakash ; Diwan, Prakash V ; Ansari, Siddique Akber ; Sangshetti, Jaiprakash N</creatorcontrib><description>Diabetes is one of the most common disorders that substantially contributes to an increase in global health burden. As a metabolic disorder, diabetes is associated with various medical conditions and diseases such as obesity, hypertension, cardiovascular diseases, and atherosclerosis. In this review, we cover the scientific studies on sodium/glucose cotransporter (SGLT) inhibitors published during the last decade. Our focus on providing an exhaustive overview of SGLT inhibitors enabled us to present their chemical classification for the first time. Diabetes is one of the most common disorders that substantially contributes to an increase in global health burden.</description><identifier>ISSN: 2046-2069</identifier><identifier>EISSN: 2046-2069</identifier><identifier>DOI: 10.1039/c9ra08706k</identifier><identifier>PMID: 35494673</identifier><language>eng</language><publisher>England: Royal Society of Chemistry</publisher><subject>Atherosclerosis ; Chemistry ; Diabetes ; Hypertension ; Inhibitors ; Metabolic disorders ; Organic chemistry</subject><ispartof>RSC advances, 2020-01, Vol.1 (3), p.1733-1756</ispartof><rights>This journal is © The Royal Society of Chemistry.</rights><rights>Copyright Royal Society of Chemistry 2020</rights><rights>This journal is © The Royal Society of Chemistry 2020 The Royal Society of Chemistry</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-6b213bf234c7940e45212be9b579ed109d051a587b9964a09a59247fdcc2eb723</citedby><cites>FETCH-LOGICAL-c428t-6b213bf234c7940e45212be9b579ed109d051a587b9964a09a59247fdcc2eb723</cites><orcidid>0000-0003-4787-3944 ; 0000-0002-9064-4111</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048284/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048284/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35494673$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kshirsagar, Rahul P</creatorcontrib><creatorcontrib>Kulkarni, Abhishek A</creatorcontrib><creatorcontrib>Chouthe, Rashmi S</creatorcontrib><creatorcontrib>Pathan, Shahebaaz K</creatorcontrib><creatorcontrib>Une, Hemant D</creatorcontrib><creatorcontrib>Reddy, G. Bhanuprakash</creatorcontrib><creatorcontrib>Diwan, Prakash V</creatorcontrib><creatorcontrib>Ansari, Siddique Akber</creatorcontrib><creatorcontrib>Sangshetti, Jaiprakash N</creatorcontrib><title>SGLT inhibitors as antidiabetic agents: a comprehensive review</title><title>RSC advances</title><addtitle>RSC Adv</addtitle><description>Diabetes is one of the most common disorders that substantially contributes to an increase in global health burden. As a metabolic disorder, diabetes is associated with various medical conditions and diseases such as obesity, hypertension, cardiovascular diseases, and atherosclerosis. In this review, we cover the scientific studies on sodium/glucose cotransporter (SGLT) inhibitors published during the last decade. Our focus on providing an exhaustive overview of SGLT inhibitors enabled us to present their chemical classification for the first time. Diabetes is one of the most common disorders that substantially contributes to an increase in global health burden.</description><subject>Atherosclerosis</subject><subject>Chemistry</subject><subject>Diabetes</subject><subject>Hypertension</subject><subject>Inhibitors</subject><subject>Metabolic disorders</subject><subject>Organic chemistry</subject><issn>2046-2069</issn><issn>2046-2069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpdkVtLw0AQhRdRVNQX35WALyJE956sD4VSvGFB8PK87G4mdrVN6m5S8d-b2lovw8AMzMfhDAehfYJPCWbqzKlgcJ5h-bqGtinmMqVYqvVf-xbai_EFdyUFoZJsoi0muOIyY9uo93A1fEx8NfLWN3WIiem6anzhjYXGu8Q8Q9XE88Qkrp5MA4ygin4GSYCZh_ddtFGacYS95dxBT5cXj4PrdHh3dTPoD1PHad6k0lLCbEkZd5niGLighFpQVmQKCoJVgQUxIs-sUpIbrIxQlGdl4RwFm1G2g3oL3WlrJ1C4zlMwYz0NfmLCh66N138vlR_p53qmFeY5zXkncLwUCPVbC7HREx8djMemgrqNmkqRS0Epxh169A99qdtQde9pypjAhGdi7uhkQblQxxigXJkhWM-T0QN13_9K5raDD3_bX6HfOXTAwQII0a2uP9GyT-bbkbI</recordid><startdate>20200109</startdate><enddate>20200109</enddate><creator>Kshirsagar, Rahul P</creator><creator>Kulkarni, Abhishek A</creator><creator>Chouthe, Rashmi S</creator><creator>Pathan, Shahebaaz K</creator><creator>Une, Hemant D</creator><creator>Reddy, G. Bhanuprakash</creator><creator>Diwan, Prakash V</creator><creator>Ansari, Siddique Akber</creator><creator>Sangshetti, Jaiprakash N</creator><general>Royal Society of Chemistry</general><general>The Royal Society of Chemistry</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SR</scope><scope>8BQ</scope><scope>8FD</scope><scope>JG9</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4787-3944</orcidid><orcidid>https://orcid.org/0000-0002-9064-4111</orcidid></search><sort><creationdate>20200109</creationdate><title>SGLT inhibitors as antidiabetic agents: a comprehensive review</title><author>Kshirsagar, Rahul P ; Kulkarni, Abhishek A ; Chouthe, Rashmi S ; Pathan, Shahebaaz K ; Une, Hemant D ; Reddy, G. Bhanuprakash ; Diwan, Prakash V ; Ansari, Siddique Akber ; Sangshetti, Jaiprakash N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-6b213bf234c7940e45212be9b579ed109d051a587b9964a09a59247fdcc2eb723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Atherosclerosis</topic><topic>Chemistry</topic><topic>Diabetes</topic><topic>Hypertension</topic><topic>Inhibitors</topic><topic>Metabolic disorders</topic><topic>Organic chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kshirsagar, Rahul P</creatorcontrib><creatorcontrib>Kulkarni, Abhishek A</creatorcontrib><creatorcontrib>Chouthe, Rashmi S</creatorcontrib><creatorcontrib>Pathan, Shahebaaz K</creatorcontrib><creatorcontrib>Une, Hemant D</creatorcontrib><creatorcontrib>Reddy, G. Bhanuprakash</creatorcontrib><creatorcontrib>Diwan, Prakash V</creatorcontrib><creatorcontrib>Ansari, Siddique Akber</creatorcontrib><creatorcontrib>Sangshetti, Jaiprakash N</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Engineered Materials Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Materials Research Database</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>RSC advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kshirsagar, Rahul P</au><au>Kulkarni, Abhishek A</au><au>Chouthe, Rashmi S</au><au>Pathan, Shahebaaz K</au><au>Une, Hemant D</au><au>Reddy, G. Bhanuprakash</au><au>Diwan, Prakash V</au><au>Ansari, Siddique Akber</au><au>Sangshetti, Jaiprakash N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SGLT inhibitors as antidiabetic agents: a comprehensive review</atitle><jtitle>RSC advances</jtitle><addtitle>RSC Adv</addtitle><date>2020-01-09</date><risdate>2020</risdate><volume>1</volume><issue>3</issue><spage>1733</spage><epage>1756</epage><pages>1733-1756</pages><issn>2046-2069</issn><eissn>2046-2069</eissn><abstract>Diabetes is one of the most common disorders that substantially contributes to an increase in global health burden. As a metabolic disorder, diabetes is associated with various medical conditions and diseases such as obesity, hypertension, cardiovascular diseases, and atherosclerosis. In this review, we cover the scientific studies on sodium/glucose cotransporter (SGLT) inhibitors published during the last decade. Our focus on providing an exhaustive overview of SGLT inhibitors enabled us to present their chemical classification for the first time. Diabetes is one of the most common disorders that substantially contributes to an increase in global health burden.</abstract><cop>England</cop><pub>Royal Society of Chemistry</pub><pmid>35494673</pmid><doi>10.1039/c9ra08706k</doi><tpages>24</tpages><orcidid>https://orcid.org/0000-0003-4787-3944</orcidid><orcidid>https://orcid.org/0000-0002-9064-4111</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2046-2069
ispartof RSC advances, 2020-01, Vol.1 (3), p.1733-1756
issn 2046-2069
2046-2069
language eng
recordid cdi_proquest_miscellaneous_2658652200
source PubMed Central (Open Access)
subjects Atherosclerosis
Chemistry
Diabetes
Hypertension
Inhibitors
Metabolic disorders
Organic chemistry
title SGLT inhibitors as antidiabetic agents: a comprehensive review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T19%3A57%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_rsc_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SGLT%20inhibitors%20as%20antidiabetic%20agents:%20a%20comprehensive%20review&rft.jtitle=RSC%20advances&rft.au=Kshirsagar,%20Rahul%20P&rft.date=2020-01-09&rft.volume=1&rft.issue=3&rft.spage=1733&rft.epage=1756&rft.pages=1733-1756&rft.issn=2046-2069&rft.eissn=2046-2069&rft_id=info:doi/10.1039/c9ra08706k&rft_dat=%3Cproquest_rsc_p%3E2335014752%3C/proquest_rsc_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c428t-6b213bf234c7940e45212be9b579ed109d051a587b9964a09a59247fdcc2eb723%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2335014752&rft_id=info:pmid/35494673&rfr_iscdi=true